Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Leducq Foundation grant boosts cardiovascular research

Kennedy

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

Claudia Monaco

Claudia Monaco, MD PhD, Professor of Cardiovascular Inflammation at the Kennedy Institute of Rheumatology, NDORMS and Hon. Consultant Cardiologist at the OUH NHS Trust is part of an international team that will seek to use immunotherapy to better treat atherosclerosis, the process of narrowing of the arteries that causes myocardial infarction and stroke.

The Leducq Foundation, which is dedicated to battling cardiovascular disease and stroke, has funded a total of four projects worldwide for 2022, and one of those, called CHECKPOINT ATHERO, involves researchers at Mayo Clinic USA, Radboud University Medical Center in Nijmegen in the Netherlands, University of Oxford, Lund University in Sweden, Leiden University and Geisel School of Medicine in USA, led by Esther Lutgens (Mayo) and Willem Mulder (Nijmegen).

Read the full story on the Kennedy Institute of Rheumatology website. 

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

New therapeutic target identified in spondyloarthritis

A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.

Researchers identify link in the treatment of inflammatory bowel disease (IBD)

A new study published in the Journal of Experimental Medicine reveals how IL-10 and PGE2 work together to prevent inflammatory tissue damage and maintain a healthy gut balance

Dissecting TNF signalling in inflammatory disease

New research from Dr Richard Williams’ group at the Kennedy Institute suggests a route for the development of more selective – and effective – therapies for immune-mediated inflammatory disease.

Naturally occurring compound spermidine boosts vaccine responses in old mice

A new study by Kennedy Institute's Professor Katja Simon, and colleagues published in Molecular Cell shows that spermidine, a naturally occurring metabolite found in most human cell types, boosts antibody production in both old mice and immune cells from the elderly.